| Subject: | FDA Issues Recall of Boston Scientific ENTERYX Procedure Kits and ENTERYX Injector Single Packs for Treatment of Gastroesophageal Reflux Disease |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 19 Oct 2005 - 11:43 am |
| Audience - Surgeons, Gastroenterologists, other healthcare professionals, and patients
Physicians should stop injecting ENTERYX immediately and follow the manufacturer's procedures for returning unused product.
The FDA and Boston Scientific are notifying healthcare professionals and patients about serious adverse events, including death, occurring in patients treated with ENTERYX, a liquid chemical polymer which is intended to be injected into the lower esophageal sphincter for treatment of... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
